Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clostebol→

Clostebol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1093-58-9
Molecular formula
C19H27ClO2
Molecular weight
322.9 g/mol
Drug class
Synthetic anabolic-androgenic steroid4-chlorotestosterone derivative
Mechanism of action
Activates androgen receptors and modulates androgen-responsive gene transcription, promoting anabolic and androgenic effects. It is a synthetic androgen and is prohibited in sport under anti-doping rules.
Indications / reported uses
  • Clostebol acetate has been used in some countries in topical combination products for local tissue repair and dermatological indications; product-specific use is formulation-dependent. The substance is not a general wound-care recommendation.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=clostebol · https://www.wada-ama.org/en/prohibited-list · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Clostebol Environmental Risk Assessment (ERA) (the Clostebol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.